Emerging drugs for the treatment of sepsis.

about

Human plasma kallikrein-kinin system: physiological and biochemical parameters

P2860

Q36998879-CB3BB25A-D2E4-43A6-9F50-0C587D2B7B61

P2860

Emerging drugs for the treatment of sepsis.

Item

http://www.wikidata.org/entity/Q36407391

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Emerging drugs for the treatment of sepsis.

@ast

Emerging drugs for the treatment of sepsis.

@en

type

Item

label

Emerging drugs for the treatment of sepsis.

@ast

Emerging drugs for the treatment of sepsis.

@en

prefLabel

Emerging drugs for the treatment of sepsis.

@ast

Emerging drugs for the treatment of sepsis.

@en

P1476

Emerging drugs for the treatment of sepsis.

@en

P2093

Diane Lipiner

http://www.w3.org/2001/XMLSchema#string

Jérome Aboab

http://www.w3.org/2001/XMLSchema#string

Olivier Nardi

http://www.w3.org/2001/XMLSchema#string

Tarek Sharshar

http://www.w3.org/2001/XMLSchema#string

P2860

Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis

Early goal-directed therapy in the treatment of severe sepsis and septic shock

Innate immune recognition

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

HMG-1 as a late mediator of endotoxin lethality in mice

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

Complement-induced impairment of innate immunity during sepsis

MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia

P304

7-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.11.1.7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Djillali Annane

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16503823

http://www.w3.org/2001/XMLSchema#string

P921

sepsis

Emerging drugs for the treatment of sepsis.

about

P2860

P2860

Emerging drugs for the treatment of sepsis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921